Cardiff Oncology and Pfizer assess onvansertib in metastatic colorectal cancer trial
A clinical trial is underway to evaluate onvansertib combined with standard therapies for first-line treatment of KRAS/NRAS-mutated metastatic colorectal cancer.
Asset / Drug
Drug and asset intelligence for Cardiff with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.